ESC & iPSC News

ESC & iPSC News is an online resource dedicated to the latest research in the fields of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).

Subscribe|Follow Us On

Applied StemCell and Cellipont Bioservices Partner to Offer a Seamless Path for iPSC-Derived Cell Therapy Development

March 24, 2026

[Applied StemCell, Inc. ] Applied StemCell, Inc., announced a strategic collaboration designed to streamline and accelerate the development of iPSC-derived cell therapies.

Pluripotent Stem-Cell-Based Screening Uncovers Sildenafil As a Mitochondrial Disease Therapy

March 24, 2026

[Cell] To accelerate drug discovery for Leigh syndrome (LS), scientists screen a library of 5,632 repurposable compounds in neural cells from LS-patient-derived iPSCs. They identified phosphodiesterase type 5 inhibitors as leads and prioritized sildenafil for its clinical safety.

Poking Pluripotency: Nanoinjection Into Human iPSCs

March 24, 2026

[Advanced Materials] Investigators reported a customized nanoinjection strategy enabling efficient transfection of hiPSCs with various types of reporter messenger RNA.

Nonsense-Mediated mRNA Decay Safeguards Telomeres in Pluripotent Stem Cells

March 24, 2026

[Nature Cell Biology] Researchers showed that a cellular quality control system called nonsense-mediated mRNA decay (NMD), which normally eliminates defective RNA molecules, plays an unexpected role in maintaining telomere integrity in pluripotent cells.

Endogenous VEGF Signaling Acts As a Guardian of Human Primed Pluripotency

March 24, 2026

[Nature Communications] Scientists identified a previously unrecognized role of endogenous VEGF signaling in sustaining primed hESC pluripotency.

ETV2 Mediated Differentiation of Human Pluripotent Stem Cells Results in Functional Endothelial Cells for Engineering Advanced Vascularized Microphysiological Models

March 24, 2026

[Advanced Healthcare Materials] Researchers generated multiple hiPSC lines with inducible ETV2 expression, and subsequently differentiated them into human-induced endothelial cells, which were validated functionally and by key endothelial markers and RNA-seq analysis.

miR-203 Facilitates Timely Cell Fate Transitions via Epigenetic Modulation during Early Embryogenesis

March 24, 2026

[Molecular Therapy - Nucleic Acids] In a strictly in vivo approach based on genetically engineered mouse models and single-cell RNA sequencing, scientists identified microRNA-203 (miR-203) as a critical regulator of timely progression in preimplantation mouse embryos.

Cellular Reprogramming beyond Pluripotency

March 24, 2026

[Trends In Molecular Medicine] The authors summarize genetic and chemical strategies for partial reprogramming, discuss their tissue-specific effects in vivo, and evaluate their implications for tissue regeneration and age-related disease.

Advances in the Differentiation of Induced Pluripotent Stem Cells Into Vascular Cells for the Treatment of Diabetic Microvascular Disease

March 24, 2026

[Cardiovascular Diabetology] iPSC technology offers revolutionary prospects for an autologous, limitless source of functional vascular cells, scientists summarize recent developments in differentiating iPSCs into key microvascular cell types.

Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY” in Japan

March 11, 2026

[Sumitomo Pharma Co., Ltd.] Sumitomo Pharma Co., Ltd. and and RACTHERA Co., Ltd., announced that Sumitomo Pharma has obtained conditional and time‑limited approval in Japan for the manufacturing and marketing authorization of the allogeneic iPS cell‑derived dopaminergic neural progenitor cell product AMCHEPRY^® for the indication of the improvement of motor symptoms in patients with Parkinson’s disease who have an inadequate response to existing pharmacological therapies.

Personalized Pharmacokinetic-Pharmacodynamic Guided Therapy via an Induced Pluripotent Stem Cell-Derived Multi-Organoid Platform in NF1-Mutant Breast Cancer

March 11, 2026

[Signal Transduction and Targeted Therapy] Investigators presented a personalized treatment model using a patient-derived Networking Organoid Culture System composed of intestinal, liver, and kidney organoids differentiated from iPSCs of an NF1-mutant breast cancer patient.

Generation of Functionally Competent Testicular Somatic Cells from Pluripotent Stem Cells

March 11, 2026

[Science Advances] Scientists developed a method for differentiating male ESCs into functional embryonic testicular somatic cells, building upon the approach used for fetal ovarian somatic cell–like cells.

Since 2007, ESC & iPSC News has been providing updates on the top publications, reviews, and news in pluripotent stem cell research. Through our website, Twitter, and email newsletters, our editorial team is proud to help keep researchers and medical professionals up-to-date with the latest discoveries, jobs, and event postings in the pluripotent stem cell field.